Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Saved in:
Bibliographic Details
Title: Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Authors: Schwab N; (Muenster, Germany)., Schneider-Hohendorf T; (Muenster, Germany)., Pignolet B; (Toulouse, France)., Brassat D; (Toulouse, France)., Wiendl H; (Muenster, Germany).
Source: Neurology [Neurology] 2020 Sep 15; Vol. 95 (11), pp. 505.
Publication Type: Journal Article; Comment
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1526-632X
DOI:10.1212/WNL.0000000000010513